Introduction
Recombinant activated factor VII (rFVIIa, NovoSeven, Novo Nordisk, Denmark) is an effective hemostatic agent in 75-90% of hemophiliacs with inhibitors, and in other coagulation disorders such as acquired hemophilia, congenital factor VII deficiency and Glanzmann thromboasthenia. [1] [2] [3] [4] [5] Recently, unlicensed use of rFVIIa has provided benefit in many other non-hemophilic bleeding situations unresponsive to conventional therapy to control excessive bleeding and reduce exposure to allogeneic blood. These include intracerebral hemorrhage, oral anticoagulant-induced hemorrhage, thrombocytopenia, bleeding associated with hepatic failure, major surgery, trauma and life-threatening obstetrical, and gynecologic hemorrhagic complications. [5] [6] [7] [8] [9] In this systematic review we have collected the available data from the literature on the use of rFVIIa in hematooncological patients with severe bleeding, unresponsive to standard therapy.
Literature search
We firstly performed an electronic search on hematooncology and rFVIIa on MEDLINE, EMBASE, SCOPUS, OVID and the Cochrane Library without temporal limits using different combinations of the following keywords: 'hemato-oncology', 'oncology', 'hematology', 'leukemia', 'myeloproliferative disorders', 'myelodysplastic syndromes', 'bleeding', 'hemorrhage', 'bone marrow transplant' and 'rFVIIa'. Only articles with at least an abstract in English were considered. In addition, the bibliographic references of all studies and reviews retrieved were assessed for additional reports of clinical trials. Unpublished works were identified by searching the abstract books of the most important conferences on hemato-oncological diseases. In total, we identified 74 references through electronic and hand searches. After reading the titles and abstracts, we excluded 36 irrelevant references and retrieved 38 references for further assessment. A further five studies were excluded because they were reviews (three articles) [10] [11] [12] or duplicates (two articles). Thus, a total of 33 articles/abstracts, including 162 hemato-oncological patients treated with rFVIIa, were retrieved from this literature search (31 articles and two abstracts). All the articles found, with the exception of the randomized trial by Pihusch et al., 44 were uncontrolled studies. Figure 1 shows the flowchart of inclusion of studies.
Mechanisms of action of rFVIIa
According to current knowledge, activated factor VII functions primarily through two mechanisms. The first pathway is tissue factor (TF)-dependent mechanism and involves the formation, following a vessel injury, of a TFFVIIa complex, which in turn activates FX leading to the conversion of prothrombin to thrombin. The initial limited amount of thrombin formed subsequently activates FVIII, FV and platelets so that the tenase complex (FVIIIa/FIXa) and the prothrombinase complex (FXa/FVa) assembled on the activated platelet surface lead to full thrombin generation. This 'thrombin burst' is essential for the formation of a stable fibrin clot which is resistant to premature fibrinolysis and thus provides reliable and sustained hemostasis. However, the hemostatic process is not systemic but confined to the surface of the thrombinactivated platelets and the TF-bearing cells.
The second pathway involves a TF-independent mechanism. In fact, recent data suggest that rFVIIa at high pharmacologic doses can directly activate FX leading to an additional burst of thrombin. Figure 2 illustrates the mechanisms of action of activated FVII. [46] [47] [48] The use of rFVIIa in non-transplanted hemato-oncological patients Hemato-oncological diseases are quite commonly complicated by severe hemorrhagic episodes, which may be due to factors related to the primary disorder or to chemotherapyinduced toxicity. For example, thrombocytopenia, the commonest risk factor for bleeding in hemato-oncological patients, may be a feature of the hematological malignancy (i.e., acute leukemias or myelodysplastic syndromes) or the consequence of myeloablative therapy. On the other hand, other conditions (i.e., myeloproliferative disorders) may be characterized by a normal or even increased platelet count but defective platelet function, predisposing to a bleeding tendency.
There is increasing evidence of the usefulness of rFVIIa for the treatment of severe bleeding refractory to standard transfusional therapy in patients with hemato-oncological diseases. 10 The first description was made in 1999 by White et al., 13 who described the successful use of rFVIIa in the treatment of pulmonary hemorrhage secondary to Aspergillus in a patients with acquired FVII deficiency undergoing treatment for acute myeloid leukemia (AML). The largest case series was that recently reported by Brenner et al. 27 The authors, using an Internet-based registry (www.haemostasis. com), collected 24 cases in which rFVIIa was used in the management of hemorrhage in patients with thrombocytopenia associated with hematologic malignancies. Patients Bleeding stopped in 11 of 24 patients (46%), markedly decreased in 8 of 24 patients (33%) and decreased in 4 of 24 patients (17%). In most patients, the response was achieved within 2.5 h of administration of rFVIIa. On the basis of these results, the authors suggested the beneficial effect of rFVIIa in this clinical setting. However, a case of ischemic stroke, possibly related to the use of rFVIIa, was documented.
Another severe rFVIIa-related adverse reaction was described by Mantzios et al., 34 who reported massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with AML and refractory bleeding. We recently described a 66-year-old female Jehovah's witness suffering from B-cell chronic lymphocytic leukemia and ulcerative colitis with severe hemorrhage, in whom the use of rFVIIa obviated the need for transfusions. 28 Other authors have reported the use of rFVIIa for bleeding in hemato-oncology pediatric practice. Millar et al. 29 described the use of rFVIIa in three boys (one of whom had undergone a haploidentical bone marrow transplant) with life-threatening gastrointestinal hemorrhage. However, the results were disappointing as the drug only reduced the bleeding in one case. By contrast, Das et al. 30 successfully used this agent as prophylaxis for hemorrhage in three pediatric patients before lumbar puncture. Table 1 shows the literature data on the use of rFVIIa in hemato-oncology patients outside the transplant setting. On the whole, a total of 22 articles were collected including 49 patients with hemorrhagic complications treated with rFVIIa. As expected, the bleeding site most frequently involved was the gastrointestinal tract (46.9%), due to the chemotherapy-induced mucosal damage.
The mean dose of rFVIIa administered was 82.3 mg/kg, which was similar to the hemophilia doses of 90 mg/kg. In 21 patients (42.9%), a single dose of rFVIIa was injected, although in some cases additional doses were required to achieve optimum hemostasis (median of 1.6 doses injected per episode).
As regards the assessment of the effectiveness of rFVIIa, the majority of authors defined a positive result when rFVIIa led to cessation or significant reduction in either blood loss or need for blood transfusion. Using this definition, among the 49 reported cases, a positive result was obtained in all but three cases (93.9% of efficacy). However, we advise particular caution in interpreting these results as all data available in literature were derived from uncontrolled studies including single cases or small series of patients. Thus, the real effectiveness of rFVIIa in these bleeding situations could be overestimated, those cases with a positive outcome being preferentially reported.
The use of rFVIIa in bone marrow transplant Bleeding complications are relatively common in bone marrow transplantation (BMT), [10] [11] [12] although the reported risk of hemorrhage varies widely between the different series because of differences in conditioning regimens, patient populations and diseases transplanted.
Several pathologic changes in the hemostatic system are observed in patients undergoing BMT. First of all, graftversus-host disease is strongly associated with severe gastrointestinal bleeding due to the presence of chronic inflammatory bowel disease with extensive mucosal lesions worsened by the reduction of coagulation factor XIII, which is important for wound healing. Moreover, transplant-related thrombocytopenia and liver toxicity (with the consequent reduction in plasma levels of vitamin K-dependent coagulation factors) also occur and increase the bleeding risk. Several organ systems appear to be at increased risk of bleeding in BMT patients. Pihusch et al. 49 recently conducted a retrospective evaluation of 447 hemopoietic stem cell transplantation (HSCT) patients to examine the incidence of transplant-related hemostatic complications. Interestingly, the authors observed that more than 80% of HSCT patients experienced at least one bleeding complication, with severe bleeding occurring in 27% of patients and most frequently including gastrointestinal bleeding, intracranial hemorrhage and hemorrhagic cystitis (HC). The overall mortality was doubled in those patients who experienced a severe hemorrhagic event.
Among the newer therapeutic options available for the treatment of BMT-related severe bleeding, rFVIIa appears to be the most promising. However, the published experience on the use of rFVIIa in BMT-associated hemorrhage includes mostly anecdotal reports. Table 2 analyzes the existing literature.
Henke et al. 42 reported the successful treatment of three successive patients with diffuse alveolar hemorrhage (DAH) with rFVIIa using doses of 90-160 mg/kg. Two of these cases were associated with small-vessel vasculitis, whereas the other was a BMT recipient. Hicks et al. 36 also described the successful use of rFVIIa in an individual with DAH following match unrelated BMT for acute myelogenous leukemia. This patient received 90 mg/kg every 3 h for four doses per day. The drug was initially discontinued after eight doses. However, the patient's condition deteriorated. rFVIIa was then restarted for an additional 16 doses, with resolution of the DAH.
In a study of 12 transplant patients with DAH, all received platelets, epsilon-aminocaproic acid and high-dose steroids concurrently with rFVIIa. The median doses and duration of bolus intravenous rFVIIa were 84 mg/kg/dose and 3.5 days, respectively. Six of eight patients with early DAH and one of four with late DAH survived. 40 rFVIIa has also been successfully used as treatment for refractory transplant-related HC. Karimi et al. 41 report a series of eight (4.4%) patients undergoing allogeneic transplantation who were found to have HC. Four received rFVIIa at doses ranging between 150 and 400 mg/kg/dose to achieve hemostasis. The largest dose received by one of these patients was a total of 1200 mg/kg. Bleeding stopped within 12-48 h in all patients after the drug administration. Aneel et al. 43 treated seven BMT patients with severe, refractory HC with rFVIIa using an initial dose of 80 mg/kg. Nonresponding patients or patient who re-bled were treated with 120 mg/kg. A total of three doses were permitted. Four of the seven patients had a complete response, two had a partial response (overall response 85.7%) and one did not respond.
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De Fabritiis et al. 23 reported seven patients with severe bleeding treated with rFVIIa at various doses (40-100 mg/ kg for to six doses); although a complete response was obtained in all the patients receiving chemotherapy without BMT, a reduced efficacy (three partial responses) was observed in the five transplanted cases. Interestingly, the authors found an inverse correlation between the likelihood of response to rFVIIa and the phase (early or advanced) of the primitive disease.
The only randomized trial available in the literature is the multicenter study published by Pihusch et al. 44 on behalf the F7BMT-1360-Trial Investigator Group. One hundred BMT patients with moderate or severe bleeding were randomized to receive seven doses of rFVIIa at various doses (40, 80 or 160 mg/kg) or placebo every 6 h. Despite the fact that no overall effect of increasing rFVIIa dose was observed on the primary end point (i.e., improvement in bleeding score between the first administration and at 38 h), a post hoc analysis showed an improvement in the control of bleeding for the rFVIIa 80 mg/kg group versus the standard hemostatic treatment group. Thus, the authors suggested that population heterogeneity might have contributed to the lack of an increasing effect with increasing dose and suggested further Table 1 The use of rFVIIa in critical bleeding associated with hematooncology diseases: review of the literature trials focusing on the identification of patient populations that may benefit from treatment with rFVIIa in this setting. Finally, although the rate of thromboembolic events observed in the active treatment groups (6/77 patients, 7.8%) was not dissimilar to historical controls, 49 the authors expressed their concerns regarding the use of a potentially thrombogenic agent in this setting.
On the whole, a total of 13 articles were collected in the literature including 113 BMT patients treated with rFVIIa (see Table 2 ). Gastrointestinal bleeding was the leading cause of hemorrhage (46.9%), followed by HC (31.8%) and DAH (13.3%). The median number of doses of rFVIIa administered was 96.6 mg/kg and 7.2, respectively. A response, evaluated as cessation or significant reduction of bleeding, was observed in the majority of patients (69/ 113, 61.1%). Thus, these preliminary data support the usefulness of rFVIIa in addition to standard transfusion therapy in the management of severe hemorrhage complicating BMT.
Conclusions
Although mostly based on uncontrolled studies, the available literature data suggest potential benefit of rFVIIa in the treatment of refractory critical bleeding which may complicate the clinical course in hemato-oncological disorders.
However, concerns remain regarding the incidence of drug-related thromboembolic events, especially in transplant patients with additional prothrombotic risk factors (i.e., inflammation, venocclusive disease, systemic activation of coagulation and platelet glycoproteins).
Thus, further trials on larger numbers of patients will help us not only to establish the most appropriate doses but also to better assess the safety and effectiveness of this expensive hemostatic 'bypassing' agent.
